Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis

A post hoc analysis of overall and Japanese results from phase 3 clinical trials

Yuko Kaneko, Tsutomu Takeuchi, Zhihong Cai, Masayo Sato, Kenta Awakura, Carol Gaich, Baojin Zhu, Jiaying Guo, Yoshiya Tanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To assess the determinants of Patient’s Global Assessment of Disease Activity (PtGA) and Physician’s Global Assessment of Disease Activity (PhGA) in overall and Japanese patients with rheumatoid arthritis (RA) from two large randomized controlled trials. Methods: Post hoc analysis of overall and Japanese RA patients who had previous inadequate responses to methotrexate or who had no/minimal previous disease-modifying antirheumatic drug treatment. We examined correlations between PtGA/PhGA and tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), inflammatory markers, pain visual analog scale (VAS), and other patient-reported outcomes at baseline, Week 12, and Week 24. Determinants of PtGA/PhGA were identified. Results: In overall populations, pain VAS was the main determinant of PtGA, whereas TJC28 was the main determinant of PhGA in both studies. In Japanese populations, consistent with overall populations, pain VAS was the main determinant of PtGA in both studies; in contrast to overall populations, pain VAS and SJC28/TJC28 played an important role in PhGA. Conclusion: Pain was the most important determinant of PtGA, whereas determinants of PhGA varied between populations/studies and were mostly explained by pain/joint counts. Physicians should be aware of patients’ perceptions of disease activity when performing assessments/prescribing treatments.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2018 Feb 1

Fingerprint

Phase III Clinical Trials
Rheumatoid Arthritis
Joints
Physicians
Pain Measurement
Population
Antirheumatic Agents
Arthralgia
Methotrexate
N-phthaloylglutamic acid
Randomized Controlled Trials
Pain

Keywords

  • Clinician-reported outcomes
  • discordance
  • Japan
  • patient-reported outcomes
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{7ac5db0bb8624f0184dce6a84f45fb06,
title = "Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials",
abstract = "Objectives: To assess the determinants of Patient’s Global Assessment of Disease Activity (PtGA) and Physician’s Global Assessment of Disease Activity (PhGA) in overall and Japanese patients with rheumatoid arthritis (RA) from two large randomized controlled trials. Methods: Post hoc analysis of overall and Japanese RA patients who had previous inadequate responses to methotrexate or who had no/minimal previous disease-modifying antirheumatic drug treatment. We examined correlations between PtGA/PhGA and tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), inflammatory markers, pain visual analog scale (VAS), and other patient-reported outcomes at baseline, Week 12, and Week 24. Determinants of PtGA/PhGA were identified. Results: In overall populations, pain VAS was the main determinant of PtGA, whereas TJC28 was the main determinant of PhGA in both studies. In Japanese populations, consistent with overall populations, pain VAS was the main determinant of PtGA in both studies; in contrast to overall populations, pain VAS and SJC28/TJC28 played an important role in PhGA. Conclusion: Pain was the most important determinant of PtGA, whereas determinants of PhGA varied between populations/studies and were mostly explained by pain/joint counts. Physicians should be aware of patients’ perceptions of disease activity when performing assessments/prescribing treatments.",
keywords = "Clinician-reported outcomes, discordance, Japan, patient-reported outcomes, rheumatoid arthritis",
author = "Yuko Kaneko and Tsutomu Takeuchi and Zhihong Cai and Masayo Sato and Kenta Awakura and Carol Gaich and Baojin Zhu and Jiaying Guo and Yoshiya Tanaka",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/14397595.2017.1422304",
language = "English",
pages = "1--8",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis

T2 - A post hoc analysis of overall and Japanese results from phase 3 clinical trials

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

AU - Cai, Zhihong

AU - Sato, Masayo

AU - Awakura, Kenta

AU - Gaich, Carol

AU - Zhu, Baojin

AU - Guo, Jiaying

AU - Tanaka, Yoshiya

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objectives: To assess the determinants of Patient’s Global Assessment of Disease Activity (PtGA) and Physician’s Global Assessment of Disease Activity (PhGA) in overall and Japanese patients with rheumatoid arthritis (RA) from two large randomized controlled trials. Methods: Post hoc analysis of overall and Japanese RA patients who had previous inadequate responses to methotrexate or who had no/minimal previous disease-modifying antirheumatic drug treatment. We examined correlations between PtGA/PhGA and tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), inflammatory markers, pain visual analog scale (VAS), and other patient-reported outcomes at baseline, Week 12, and Week 24. Determinants of PtGA/PhGA were identified. Results: In overall populations, pain VAS was the main determinant of PtGA, whereas TJC28 was the main determinant of PhGA in both studies. In Japanese populations, consistent with overall populations, pain VAS was the main determinant of PtGA in both studies; in contrast to overall populations, pain VAS and SJC28/TJC28 played an important role in PhGA. Conclusion: Pain was the most important determinant of PtGA, whereas determinants of PhGA varied between populations/studies and were mostly explained by pain/joint counts. Physicians should be aware of patients’ perceptions of disease activity when performing assessments/prescribing treatments.

AB - Objectives: To assess the determinants of Patient’s Global Assessment of Disease Activity (PtGA) and Physician’s Global Assessment of Disease Activity (PhGA) in overall and Japanese patients with rheumatoid arthritis (RA) from two large randomized controlled trials. Methods: Post hoc analysis of overall and Japanese RA patients who had previous inadequate responses to methotrexate or who had no/minimal previous disease-modifying antirheumatic drug treatment. We examined correlations between PtGA/PhGA and tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), inflammatory markers, pain visual analog scale (VAS), and other patient-reported outcomes at baseline, Week 12, and Week 24. Determinants of PtGA/PhGA were identified. Results: In overall populations, pain VAS was the main determinant of PtGA, whereas TJC28 was the main determinant of PhGA in both studies. In Japanese populations, consistent with overall populations, pain VAS was the main determinant of PtGA in both studies; in contrast to overall populations, pain VAS and SJC28/TJC28 played an important role in PhGA. Conclusion: Pain was the most important determinant of PtGA, whereas determinants of PhGA varied between populations/studies and were mostly explained by pain/joint counts. Physicians should be aware of patients’ perceptions of disease activity when performing assessments/prescribing treatments.

KW - Clinician-reported outcomes

KW - discordance

KW - Japan

KW - patient-reported outcomes

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85041578218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041578218&partnerID=8YFLogxK

U2 - 10.1080/14397595.2017.1422304

DO - 10.1080/14397595.2017.1422304

M3 - Article

SP - 1

EP - 8

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -